{"doi":"10.1200/jco.2022.40.16_suppl.e19082","title":"Characteristics of patients with myelofibrosis on ruxolitinib for three or more years.","abstract":"e19082 Background: Ruxolitinib (RUX) was the first JAK1/2 inhibitor approved for patients with advanced phase of myelofibrosis (MF) with median therapy duration of about 3 years. We aimed to characterize clinical features of patients treated with RUX for ≥3 years who presented to our institution between January 2000 and January 2019. Methods: Retrospective review of medical records of 131 patients who received RUX for ≥3 years. Clinical characteristics, therapy details and overall survival (OS; Kaplan Meier method) were assessed at/from the time of RUX initiation. Cox proportional hazard model was used for univariate (known clinical variables) and multivariate analysis (p < 0.05 on previous analysis) of factors associated with OS. Results: Median age of patients was 67 years (range, 31-84), 56% were males (clinical characteristics in Table). Among 62 patients with ≥ 28 gene next generation sequencing; 19, 24 and 19 patients had none, 1 and ≥2 mutations beyond JAK2, MPL, CALR, respectively. Eighty four percent of patients received RUX as frontline therapy. Median time to RUX from presentation and from MF was 4 (range, 0.1-123) and 11 months (range, 0.1-228), respectively. Starting dose of RUX was ≥ 15 mg, 10 mg and 5 mg twice daily in 110 (84%), 17 (13%), and 4 (3%) patients, respectively. Median duration of RUX therapy was 76 months (95% CI, 56-88). At the time of last follow-up (median duration of 104 months; 95% CI, 93-115), 44 patients (35%) were on RUX. Reasons for discontinuation in the remaining patients included MF progression (n = 54; 62%), blastic phase (n = 7; 8%), cytopenias (n = 4; 5%) and unrelated causes (n = 22, 25%). Median OS since therapy start was 90 months (95% CI, 76-104) with 40% of patients being alive at 10 years. Patients ≥ 65 years had median OS of 76 months (95% CI, 67-85). Patients with intermediate 2 (n = 81) or high risk (n = 29) DIPSS at RUX start had median OS of 89 (95% CI, 71-107) and 72 (95% CI, 55-89) months, respectively. Factors affecting OS on univariate analysis (HR, 95% CI, p-value) were age > 65 years (2.56, 1.49-4.35, < 0.001), neutrophils % (0.97, 0.95-0.99, 0.006), blasts % (1.213, 1.035-1.421, 0.017), performance status of <2 (0.228, 0.069-0.752, 0.015). The only factors retaining significance on multivariate analysis were age > 65 years (2.7, 1.50-4.14, < 0.001) and neutrophils % (0.66, 0.29- 0.86, 0.012). Conclusions: Forty percent of patients who remained on RUX for ≥3 years were alive at 10 years since their therapy initiation. Age remains the major predictive factor of survival despite long RUX therapy.[Table: see text]","journal":"Journal of Clinical Oncology","year":2022,"id":309205,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7938,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":232848,"name":"Prithviraj Bose","orcid":"0000-0002-4343-5712","position":1,"is_corresponding":false},{"id":232838,"name":"Naveen Pemmaraju","orcid":"0000-0002-1670-6513","position":2,"is_corresponding":false},{"id":665360,"name":"Helen T. Chifotides","orcid":"0000-0001-8044-4960","position":3,"is_corresponding":false},{"id":665361,"name":"Lingsha Zhou","orcid":"0000-0002-7981-8766","position":4,"is_corresponding":false},{"id":232851,"name":"Zeev Estrov","orcid":"0000-0002-1623-3613","position":5,"is_corresponding":false},{"id":109598,"name":"Hagop M. Kantarjian","orcid":"0000-0002-1908-3307","position":6,"is_corresponding":false},{"id":232854,"name":"Srđan Verstovšek","orcid":"0000-0002-6912-8569","position":7,"is_corresponding":false},{"id":232852,"name":"Lucia Masárová","orcid":"0000-0001-6624-4196","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T00:33:11.579763Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}